83 related articles for article (PubMed ID: 24719485)
1. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
2. Patterns of regional cerebral hypoperfusion in early Parkinson's disease: Clinical implications.
Chung SJ; Kim SH; Park CW; Lee HS; Yun M; Kim YJ; Sohn YH; Jeong Y; Lee PH
Parkinsonism Relat Disord; 2024 Apr; 121():106024. PubMed ID: 38377658
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of levodopa-induced dyskinesias.
Niccolini F; Rocchi L; Politis M
Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
[TBL] [Abstract][Full Text] [Related]
4. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
Schneider JS; Cambi F; Gollomp SM; Kuwabara H; Brašić JR; Leiby B; Sendek S; Wong DF
J Neurol Sci; 2015 Sep; 356(1-2):118-23. PubMed ID: 26099170
[TBL] [Abstract][Full Text] [Related]
5. White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease.
Jung JH; Kim YJ; Chung SJ; Yoo HS; Lee YH; Baik K; Jeong SH; Lee YG; Lee HS; Ye BS; Sohn YH; Jeong Y; Lee PH
J Neurol; 2022 Jun; 269(6):2948-2960. PubMed ID: 34762146
[TBL] [Abstract][Full Text] [Related]
6. Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease.
Yoo HS; Kim HK; Lee HS; Yoon SH; Na HK; Kang SW; Lee JH; Ryu YH; Lyoo CH
J Neurol; 2024 Jun; ():. PubMed ID: 38839638
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Marek K; Seibyl J; Eberly S; Oakes D; Shoulson I; Lang AE; Hyson C; Jennings D;
Neurology; 2014 May; 82(20):1791-7. PubMed ID: 24759846
[TBL] [Abstract][Full Text] [Related]
8. Can levodopa-induced dyskinesias go beyond the motor circuit?
Rothwell JC; Obeso JA
Brain; 2015 Feb; 138(Pt 2):242-4. PubMed ID: 25627235
[No Abstract] [Full Text] [Related]
9. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
Pilleri M; Antonini A
Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
[TBL] [Abstract][Full Text] [Related]
10. The acute brain response to levodopa heralds dyskinesias in Parkinson disease.
Herz DM; Haagensen BN; Christensen MS; Madsen KH; Rowe JB; Løkkegaard A; Siebner HR
Ann Neurol; 2014 Jun; 75(6):829-36. PubMed ID: 24889498
[TBL] [Abstract][Full Text] [Related]
11. Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson's disease.
Kim JE; Lee HS; Jang W
Front Aging Neurosci; 2023; 15():1282367. PubMed ID: 38020782
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.
di Biase L; Pecoraro PM; Carbone SP; Caminiti ML; Di Lazzaro V
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445461
[TBL] [Abstract][Full Text] [Related]
13. Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
Conti Mazza MM; Centner A; Werner DF; Bishop C
Brain Res; 2023 Jul; 1811():148381. PubMed ID: 37127174
[TBL] [Abstract][Full Text] [Related]
14. Extra-Basal Ganglia Brain Structures Are Related to Motor Reserve in Parkinson's Disease.
Youn J; Won JH; Kim M; Kwon J; Moon SH; Kim M; Ahn JH; Mun JK; Park H; Cho JW
J Parkinsons Dis; 2023; 13(1):39-48. PubMed ID: 36565134
[TBL] [Abstract][Full Text] [Related]
15. Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson's disease.
Lee SH; Kim M; Lee J; Kim JW; Kim MS; Jo S; Jeon SR; Chung SJ
Sci Rep; 2022 Oct; 12(1):16870. PubMed ID: 36207312
[TBL] [Abstract][Full Text] [Related]
16. High PSQI score is associated with the development of dyskinesia in Parkinson's disease.
Tang X; Yang J; Zhu Y; Gong H; Sun H; Chen F; Guan Q; Yu L; Wang W; Zhang Z; Li L; Ma G; Wang X
NPJ Parkinsons Dis; 2022 Sep; 8(1):124. PubMed ID: 36175559
[TBL] [Abstract][Full Text] [Related]
17. 60 Years of Achievements by KSNM in Neuroimaging Research.
Kim JS; Son HJ; Oh M; Lee DY; Kim HW; Oh J
Nucl Med Mol Imaging; 2022 Feb; 56(1):3-16. PubMed ID: 35186156
[TBL] [Abstract][Full Text] [Related]
18. Functional
Löhle M; Mangone G; Hermann W; Hausbrand D; Wolz M; Mende J; Reichmann H; Hermann A; Corvol JC; Storch A
Parkinsons Dis; 2022; 2022():5597503. PubMed ID: 35096365
[TBL] [Abstract][Full Text] [Related]
19. Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.
Palermo G; Giannoni S; Bellini G; Siciliano G; Ceravolo R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681899
[TBL] [Abstract][Full Text] [Related]
20. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
Hong JY; Sunwoo MK; Yoon JH; Kang SY; Sohn YH; Lee PH; Kim SH
PLoS One; 2020; 15(8):e0237472. PubMed ID: 32817705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
